MARKET EYE-India's Sun Pharma gains on US nod for cancer drug

Tue Feb 5, 2013 12:10pm IST

Related Topics

Stocks

   

* Shares in India's Sun Pharmaceutical Industries Ltd 
rose as much as 4.5 percent after the U.S. Food and Drug
Administration approved its generic version of ovarian cancer
drug Doxil made by Johnson & Johnson in the U.S. market.
 
* "Doxil generic approval came in as a positive surprise. This
would add US$70-$100m in high margin sales for FY14 until
further generic competition comes in," CLSA said in a note on
Tuesday.
* Shares in the drugmaker also gained after subsidiary Taro
Pharmaceutical Industries Ltd posted a 42 percent
growth in October-December net profit. 
* Sun Pharma shares were up 3.7 percent as of 0631 GMT.

 (abhishek.vishnoi@thomsonreuters.com /; kaustubh.
kulkarni@thomsonreuters.com)
FILED UNDER:
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.

  • Most Popular
  • Most Shared

Public Health

REUTERS SHOWCASE

Cost Cutting

Cost Cutting

PM Narendra Modi boots officials out of the first class cabin  Full Article 

Airtel Profit Jumps

Airtel Profit Jumps

Bharti Q2 net profit more than doubles   Full Article 

Leisure Riding

Leisure Riding

Harley-Davidson woos affluent young Indians with bike culture  Full Article 

Maruti Earnings

Maruti Earnings

Maruti Suzuki net profit up 29 percent, beats estimates.  Full Article 

ICICI Results

ICICI Results

ICICI Bank Q2 profit up 15 percent, beats estimates.  Full Article 

Moody's on India

Moody's on India

Moody's welcomes India's policy steps, but wants to see more.  Full Article 

End Of QE

End Of QE

U.S. Fed ends bond buying, exhibits confidence in U.S. recovery.  Full Article 

Cook Comes Out

Cook Comes Out

Apple's Cook: "I'm proud to be gay"  Full Article 

Refining Margins

Refining Margins

BPCL aims to double refining margins with refinery expansion.  Full Article 

Reuters India Mobile

Reuters India Mobile

Get the latest news on the go. Visit Reuters India on your mobile device  Full Coverage